Compare TCBI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBI | XENE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | N/A | 2014 |
| Metric | TCBI | XENE |
|---|---|---|
| Price | $97.12 | $41.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $98.18 | $54.09 |
| AVG Volume (30 Days) | 382.1K | ★ 1.0M |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 430.47 | N/A |
| EPS | ★ 6.79 | N/A |
| Revenue | ★ $1,200,779,000.00 | $7,500,000.00 |
| Revenue This Year | $14.76 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | $14.29 | ★ N/A |
| Revenue Growth | ★ 38.76 | N/A |
| 52 Week Low | $59.37 | $26.74 |
| 52 Week High | $105.36 | $46.60 |
| Indicator | TCBI | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 48.95 |
| Support Level | $96.25 | $40.81 |
| Resistance Level | $105.36 | $42.00 |
| Average True Range (ATR) | 2.90 | 2.01 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 40.23 | 53.52 |
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.